FDA Clears NexSys PCS Plasma System With Persona PLUS
BOSTON, Feb. 23, 2026 — Haemonetics Corporation announced that the U.S. Food and Drug Administration granted 510(k) clearance for...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
BOSTON, Feb. 23, 2026 — Haemonetics Corporation announced that the U.S. Food and Drug Administration granted 510(k) clearance for...
SAN JOSE, Calif., Feb. 23, 2026 — Anixa Biosciences announced that immunology leader Jose Conejo-Garcia, M.D., Ph.D., will keynote...
SAN DIEGO, Calif. & CAMBRIDGE, Mass., Feb. 9, 2026 — Clinical-stage life science technology company Iambic Therapeutics has entered...
SAN JOSE, Calif., Feb. 9, 2026 — Anixa Biosciences reported encouraging survival observations from its ongoing Phase 1 ovarian...
